Abstract
Liver cancer is a widespread and deadly disease without effective treatment. Utilizing the liver's affinity for iron to leverage ferroptosis provides a new direction in treating liver tumors. Herein, we develop an iron single atom-graphene oxide (Fe1-GO) composite as a novel therapeutic agent for liver cancer treatment. Through exogenously introducing iron species and targeting the liver, Fe1-GO promotes ferroptosis and exerts an anti-tumor effect. In vitro experiments demonstrate Fe1-GO's potential to inhibit cell proliferation and induce reactive oxygen species production, triggering apoptosis and pyroptosis, alongside ferroptosis. Key proteins such as ferritin and GPX4, crucial in the regulation of ferroptosis, are found to be downregulated following Fe1-GO treatment. Fe1-GO's effectiveness in reducing tumor size has been confirmed in vivo using a liver cancer model in mice, showcasing its potential as an anti-tumor agent with good biocompatibility. This work paves the way for developing new therapeutic strategies for liver cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
